Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company that regularly issues news on its drug discovery platform, clinical programs, and strategic collaborations. The company emphasizes its predictive AI/ML-powered computational discovery platform, Unigen™, which it uses to identify novel drug targets and biological pathways for immuno-oncology therapies.
News about Compugen often highlights progress across its key clinical-stage assets. Updates include data and trial milestones for COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and COM902, a potential best-in-class Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development. The company also reports on GS-0321 (previously COM503), a potential first-in-class, high-affinity anti-IL-18 binding protein antibody licensed to Gilead, and on rilvegostomig, a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca under license from Compugen.
Investors following CGEN news can expect coverage of clinical trial initiations and updates, such as the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer, pooled analyses of Phase 1 trials in platinum-resistant ovarian cancer, and first-in-human studies of GS-0321 in advanced solid malignancies. Company communications also describe partner-led studies of rilvegostomig in indications including non-small cell lung cancer and bladder cancer.
In addition, Compugen’s news flow includes quarterly financial results, cash runway commentary, amendments to collaboration agreements such as royalty monetization transactions with AstraZeneca, and participation in scientific and investor conferences. The CGEN news page on Stock Titan aggregates these announcements so readers can track clinical, financial, and partnership developments from a single source.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has scheduled the release of its first quarter 2025 financial results for Monday, May 19, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET where management will discuss the results and provide a corporate update. Investors can join via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the company's website. A replay will be available on their website after the live event.
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, has announced its participation in three major virtual investor conferences in April 2025:
- H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, featuring a fireside chat at 9:30 am ET
- 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat scheduled for 8:00 am ET
- Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, including a fireside chat at 12:00 pm ET
All events will include fireside chats and one-on-one meetings. Live webcasts will be available on Compugen's website investor relations page, with replays accessible after the events.
Compugen (NASDAQ: CGEN) reported its Q4 and full year 2024 results, highlighting significant progress in its cancer immunotherapy pipeline. The company is set to initiate a randomized adaptive platform trial for COM701 maintenance therapy in platinum-sensitive ovarian cancer in Q2 2025. Clinical data from SITC 2024 supports the further development of COM701 as a first-in-class anti-PVRIG antibody.
Financial highlights include a strong cash position of $103.3 million as of December 31, 2024, with runway expected into 2027. The company reported revenues of $27.9 million for 2024, compared to $33.5 million in 2023. Net loss for 2024 was $14.2 million ($0.16 per share), improved from $18.8 million ($0.21 per share) in 2023.
Partner developments include AstraZeneca's expansion of the rilvegostomig program to seven Phase 3 trials, and Gilead's initiation of Phase 1 trials for GS-0321, which triggered a $30 million milestone payment to Compugen in 2024.
Compugen (Nasdaq: CGEN) reported its Q4 and full-year 2024 results, highlighting significant progress in its cancer immunotherapy pipeline. The company presented promising clinical data at SITC 2024 for COM701, their first-in-class anti-PVRIG antibody, and plans to initiate a randomized trial for ovarian cancer treatment in Q2 2025.
Key developments include:
- First patient dosed in Phase 1 trial of GS-0321 (previously COM503) licensed to Gilead
- Partner AstraZeneca expanded rilvegostomig program to seven Phase 3 trials
- Strong financial position with $103.3 million cash balance as of December 31, 2024
- 2024 revenues of $27.9 million compared to $33.5 million in 2023
- Net loss of $14.2 million for 2024, improved from $18.8 million loss in 2023
The company's cash runway is expected to fund operations into 2027, supported by milestone payments from partnerships with AstraZeneca and Gilead.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company will engage in a fireside chat scheduled for March 11, 2025, at 8:00 AM ET in Miami Beach, Florida.
Investors and interested parties can access a live webcast of the presentation through the events page in the Investor Relations section of Compugen's website (www.cgen.com). A replay option will be made available after the live event concludes.
Compugen (NASDAQ: CGEN) has announced the enhancement of its AI/ML predictive computational discovery platform, Unigen™, through collaboration with Ultima Genomics' single cell sequencing technology. The partnership combines Compugen's platform with Ultima's UG 100™ sequencing platform to gain deeper insights into tumor biology and immune regulation.
Key findings presented at the AGBT 2025 General Meeting revealed high consistency in single-cell expression levels between Ultima's UG 100 and Illumina's Novaseq 6000 platforms. The UG 100 demonstrated superior capability in identifying 3' mRNA transcript endings, potentially advancing the understanding of gene structure in tumor biology.
The collaboration aims to leverage Ultima's technology for developing proprietary single cell atlases to accelerate new immunotherapy discoveries. The research findings contribute to Unigen's predictive models, with potential applications in developing new cancer immunotherapies.
Compugen (CGEN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open. The clinical-stage cancer immunotherapy company will host a conference call and webcast at 8:30 am ET, where management will review financial results and provide a corporate update.
Investors can access the conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A live webcast will be available through Compugen's website, with a replay accessible afterward.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual conference on February 11, 2025, at 8am ET.
Investors and interested parties can access a live webcast of the presentation through the Investor Relations section of Compugen's website at www.cgen.com. For those unable to attend the live session, a replay will be made available after the event.